An observational study in Melanoma; Renal Cell Carcinoma, sponsored by Indiana University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-27.
Sponsored by Indiana University · Observational
The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.
Spontaneous regression in patients with metastatic cancer is an incredibly rare event. It has been described after infection in cancer patients and also rarely in patients with renal cell cancer (usually after resection of the renal primary) and, less commonly, in patients with metastatic melanoma.
Primary Objective To collect peripheral blood from patients with metastatic melanoma and renal cell cancer and spontaneous regression for studies of immune response and other studies.
Secondary Objective To collect clinical data from subjects registered to this study. Clinical data collection will include demographics and cancer characteristics, history and treatment.
3,006 studies on the registry are indexed under Melanoma; 520 are open to participants now.
This study's enrollment of 19 is below the median of 182 across 438 observational studies indexed under Melanoma.
Browse Melanoma studies →Indiana University is the lead sponsor of 958 studies on the registry; 200 are open to participants now.
Of its 142 completed or terminated interventional studies of FDA-regulated products, 112 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with metastatic melanoma and renal cell cancer and spontaneous regression.
Exclusion Criteria
Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
Other: Blood collection for laboratory studies · Other: Data collection from medical record
Peripheral whole blood will be collected
Clinical data such as demographics and cancer characteristics, history and treatment will be collected
Number of blood samples collected
samples collected from metastatic melanoma and renal cell cancer patients
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Indiana University